Comparative Pharmacology
Head-to-head clinical analysis: ILLUCCIX versus LYMPHOSEEK KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILLUCCIX versus LYMPHOSEEK KIT.
ILLUCCIX vs LYMPHOSEEK KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle, leading to bronchodilation.
Technetium Tc-99m tilmanocept is a receptor-targeted radiopharmaceutical that binds to the mannose-binding protein (CD206) expressed on macrophages and dendritic cells within lymph nodes. It is used for lymphatic mapping and sentinel lymph node detection.
10 mg orally once daily, with or without food.
Pre-dose: 20 mcg (0.5 mL) intradermally followed by 0.5 mL subcutaneously of the same dose 15-30 minutes later. Imaging: After 24 hours, 2 mL (20 mcg) subcutaneously.
None Documented
None Documented
Terminal elimination half-life is 4–6 hours in patients with normal hepatic function; may be prolonged in hepatic impairment.
6 hours (physical half-life of technetium-99m). Effective half-life is approximately 6 hours, allowing imaging up to 24 hours post-injection.
Primarily hepatic metabolism with renal elimination of metabolites: ~30% unchanged in urine, <5% in feces.
Renal: 100% (as technetium-99m pertechnetate). No biliary or fecal elimination.
Category C
Category C
Radiopharmaceutical Diagnostic Agent
Radiopharmaceutical Diagnostic Agent